Trial Profile
A Global Study to Investigate Combination Regimens Containing Margetuximab for the Treatment of Gastric Cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2018
Price :
$35
*
At a glance
- Drugs Margetuximab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 12 Dec 2018 New trial record
- 29 Nov 2018 According to a MacroGenics media release, MacroGenics and Zai Lab Limited have entered into an exclusive collaboration and license agreement involving three immuno-oncology programs from MacroGenics pipeline of product candidates. As part of this agreement, both the companies intend to initiate this global study using combination regimens containing margetuximab in order to maximize potential clinical benefit in gastric cancer.